Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

7-17-2010

Antipsychotic Adherence, Switching, and Health Care Service
Utilization among Medicaid Recipients with Schizophrenia
Douglas L. Noordsy
Dartmouth College

Glenn A. Phillips
Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN

Daniel E. Ball
Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN

Walter T. Linde-Zwirble
ZD Associates, Perkasie, PA, USA

Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medicine and Health Sciences Commons

Dartmouth Digital Commons Citation
Noordsy, Douglas L.; Phillips, Glenn A.; Ball, Daniel E.; and Linde-Zwirble, Walter T., "Antipsychotic
Adherence, Switching, and Health Care Service Utilization among Medicaid Recipients with Schizophrenia"
(2010). Dartmouth Scholarship. 3639.
https://digitalcommons.dartmouth.edu/facoa/3639

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Patient Preference and Adherence

Dovepress
open access to scientific and medical research

O r i g i nal R e s e a r c h

Open Access Full Text Article

Antipsychotic adherence, switching, and health
care service utilization among Medicaid recipients
with schizophrenia
This article was published in the following Dove Press journal:
Patient Preference and Adherence
17 July 2010
Number of times this article has been viewed

Douglas L Noordsy 1
Glenn A Phillips 2
Daniel E Ball 2
Walter T Linde-Zwirble 3
1
Department of Psychiatry,
Dartmouth Medical School, Lebanon,
NH, USA; 2Global Health Outcomes,
Eli Lilly and Company, Indianapolis,
IN, USA; 3ZD Associates, Perkasie,
PA, USA

Objective: To evaluate health care resource utilization in patients with schizophrenia who
continued newly prescribed antipsychotic medications, compared with those switching to
different treatments.
Methods: Adults with schizophrenia in the California Medicaid (MediCal) database who
initiated treatment with index medications in 1998–2001, were classified as having: 1) abandoned
antipsychotic medications; 2) switched to another medication; or 3) continued with the index
antipsychotic, for up to 6 months after the index date.
Results: Of 2300 patients meeting eligibility criteria, 1382 (60.1%) continued index medications,
480 (20.9%) switched, and 438 (19.0%) abandoned antipsychotic treatment. Utilization in several
resource categories occurred significantly more frequently among patients whose regimens were
switched (vs those continuing index medications). These included using psychiatric (24.2% vs 14.5%;
P , 0.001) or nonpsychiatric (31.5% vs 24.3%; P , 0.05) emergency services; being admitted to a
hospital (10.6% vs 7.4%; P , 0.05); making nonpsychiatric outpatient hospital visits (43.3% vs 36.4%;
P , 0.05) or nonpsychiatric physician visits (62.7% vs 56.4%; P , 0.05); and using other outpatient
psychiatric (53.3% vs 40.7%; P , 0.001) or nonpsychiatric (82.7% vs 74.6%; P , 0.001) services.
Conclusions: Switching antipsychotic medications is associated with significantly increased
health care resource utilization (vs continuing treatment).
Keywords: antipsychotics, drug therapy, resource use, treatment adherence
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Many patients with schizophrenia experience suboptimal treatment outcomes with their
initially prescribed antipsychotic agent and require a clinically warranted medication
switch.1–4 Although medication switches represent sound “rescue” options, they are also
typically indicative of suboptimal treatment outcomes with the first therapy.5–8 Patients
for whom psychotropic medications prove to be ineffective may experience worse or
more prolonged symptoms, have more marked progression of their illness, and, in severe
cases, harm themselves or others.9–11 However, the implications of such adverse treatment
outcomes with respect to health care resource utilization are unclear. The objective of
the present study was to compare health care resource utilization among patients with
schizophrenia who switched to a different antipsychotic medication, with resource utilization among those who continued on their newly prescribed antipsychotic medication.

Methods
Study design and population
This exploratory retrospective analysis evaluated a sample of patients from the MediCal
administrative claims database treated during the period of October 1, 1998 through
Patient Preference and Adherence 2010:4 263–271
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September 30, 2001. MediCal is a large, prepaid health plan
with an enrollment of approximately 8.5 million participants
in 2001.12
The index date was the earliest date of an antipsychotic
medication prescription for which there was no prescription for the same medication in the preceding 90 days.
Eligible patients were aged 18 to 50 years and continuously
enrolled in Medicaid from 90 days before the index date
until 180 days after the index date. In addition, patients were
required to meet 1 of the following definitions of schizophrenia: a) 1 inpatient or 2 or more outpatient claims with
an International Classification of Diseases, Ninth Revision
(ICD-9) diagnostic code of 295.xx in the year before the
index date; or b) 1 outpatient claim with an ICD-9 diagnostic
code of 295.xx before or on the index date and 1 or more
claims with the same diagnostic code within 180 days of the
index date. Eligible patients were also required to have initiated a single index antipsychotic on the index date. Patients
dually enrolled in Medicaid and Medicare were excluded
because the MediCal database did not contain detailed claims
on Medicare-covered inpatient hospitalizations.

Definitions and assessments
Patients were designated by medication start categories on the
basis of prescriptions filled before the index date (Table 1).
Patients with no antipsychotic prescriptions filled in the year
preceding the index date were defined as new users; those
who filled an antipsychotic prescription 91 to 365 days before
the index date, but did not fill a prescription in the 90 days

immediately preceding the index date, were defined as restarters. Those who filled prescriptions for any antipsychotic during
the 90 days before the index date were defined as established
users.
Prescription claims were tracked beginning on the index
date to determine if patients continued their index medication, and these data were used to assign patients to outcome
categories. “Continued” patients filled pharmacy claims for
the index medication (alone or with augmentation) during the
reference period, defined as days 91 to 180 after the index
date. “Switched” patients discontinued the index medication
and switched to a nonindex antipsychotic, as documented by
pharmacy claims during the reference period. “Abandoned”
patients discontinued antipsychotics altogether (no antipsychotic pharmacy claims) during the reference period. Medicaid
service utilization was assessed for 180 days after the index
date. Categories of service use included emergency room
(ER) visits, inpatient hospitalizations, outpatient hospital care,
physician visits, and other outpatient services. Service use for
each of these categories was analyzed according to whether
the service was coded as psychiatric or nonpsychiatric, with
each patient categorized according to whether they did or
did not use that type of service. We did not conduct analyses
according to the intensity of service use by patients.
Baseline patient characteristics were determined retrospectively for both the start and outcome categories. High-intensity
comorbidities were ascertained using the diagnostic categories
defined in the Chronic Illness and Disability Payment System
(CDPS), a diagnostic classification system employed by

Table 1 Patient characteristics by start categories
Start category

No. (%)
Age, mean (SD), y
Gender, male, %
Race/ethnicity, %
White
Black
Unknown
 Hispanic
Other
Comorbid conditions, mean (SD), %
Patients with high intensity
comorbidity,a %
Patients with prior period
psychiatric ER use, %
Patients with prior period
psychiatric hospital stay, %

P

New

Restart

Established

New vs Restart

New vs Established

Restart vs
Established

622 (27.0)
36.7 (8.5)
56.3

632 (27.5)
37.1 (8.2)
55.4

1046 (45.5)
37.2 (7.9)
56.9

46.3
25.4
24.8
2.1
1.4
3.9 (3.6)
19.9

44.0
23.9
29.4
1.6
1.0
5.1 (3.6)
26.3

49.0
18.2
31.6
0.6
0.6
5.8 (3.4)
34.1

–
0.363
0.776
0.318
–
–
–
–
–
,0.001
0.007

–
0.273
0.838
,0.001
–
–
–
–
–
,0.001
,0.001

–
0.953
0.576
0.007
–
–
–
–
–
,0.001
0.001

12.1

7.6

7.9

0.010

0.007

0.851

5.3

2.7

1.8

0.021

,0.001

0.230

Determined using categories defined in the Chronic Illness and Disability Payment System.13
Abbreviations: SD, standard deviation; ER, emergency room.
a
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Medicaid to make health-based payments.13 Diagnoses
recorded in the medical claims are categorized by diagnostic
category (eg, psychiatric, cardiovascular, cancer, diabetes)
and within each diagnostic category, a ranking of intensity
from very high to extra low based upon the Medicaid costs
associated with treating patients in that group. For example in
the psychiatric category, schizophrenia is classified as high;
bipolar affective disorder as medium; and other depression,
panic disorder, and phobic disorder each as low. We defined
high-intensity comorbidities as those with CDPS rankings of
high or very high.”

Statistical analyses
Chi-square analyses were conducted to compare proportions
of patients utilizing health care services between start and
outcome categories. Tests of significance were conducted at
an a priori two-tailed α = 0.05.

Results
Of 64,324 unique antipsychotic users during the study
period, 3990 met the study inclusion criteria, and 2300 were
Medicaid-only recipients eligible for the study. In all, 622
(27.0%) patients were categorized as new users, 632 (27.5%)
as restarters, and 1046 (45.5%) as established users.
Six months after the index date, 1382 (60.1%) patients
continued on their index medication, 480 (20.9%) switched
to another antipsychotic, and 438 (19.0%) abandoned
antipsychotic treatment (Table 2). As shown in Table 2,
individuals who abandoned antipsychotic medications had a

significantly different race/ethnic distribution than those who
continued (P , 0.001) and those who switched (P = 0.001).
The group who abandoned antipsychotic treatment included
relatively more individuals categorized as black. It should
be noted that all groups had over 25% listed as unknown.
Patients who switched antipsychotic medications had a significantly higher mean number of comorbid conditions versus
those continuing (P , 0.001) and versus those abandoning
(P = 0.001) index medications. Previous psychiatric ER
visits were significantly more common among patients who
abandoned antipsychotics compared to those who continued
(P , 0.001) and those who switched (P = 0.007), respectively
and among patients who switched antipsychotics compared to
those who continued (P = 0.020). Similar to the prior psychiatric ER visit findings, those who abandoned antipsychotics
experienced higher rates of previous psychiatric hospitalizations compared to those who continued (P = 0.005) and those
who switched (P = 0.015), respectively.

Aggregate treatment outcome
comparisons
As shown in Figure 1a, significantly higher proportions
of patients who switched antipsychotic medications were
admitted to any hospital (10.6% vs 7.4%; P , 0.05 vs those
continuing), including medical admissions (8.1% vs 5.0%;
P , 0.05) but not psychiatric admissions.
Individuals who switched antipsychotics were also significantly more likely to use a range of outpatient health care
services, with the pattern for those who abandoned differing

Table 2 Patient characteristics by outcome categories
Outcome category

No. (%)
Age, mean (SD), y
Gender, male, %
Race/ethnicity, %
White
Black
Unknown
 Hispanic
Other
Comorbid conditions,mean (SD), %
Patients with high intensity
comorbidity,a %
Patients with prior period
psychiatric ER use, %
Patients with prior period
psychiatric hospital stay, %

P

Switched

Continued

Abandoned

Switched vs
Continued

Switched vs
Abandoned

Continued vs
Abandoned

480 (20.9)
36.6 (8.0)
52.7

1382 (60.1)
37.1 (8.1)
57.1

438 (19.0)
37.3 (8.4)
57.8

48.0
18.6
30.9
1.5
1.0
5.7 (3.5)
30.6

48.7
19.5
29.7
1.2
0.9
4.9 (3.6)
27.7

40.3
32.3
25.6
1.1
0.7
4.9 (3.7)
26.7

–
0.257
0.096
0.970
–
–
–
–
–
,0.001
0.240

–
0.221
0.127
0.001
–
–
–
–
–
0.001
0.188

–
0.689
0.843
,0.001
–
–
–
–
–
0.869
0.667

9.8

6.5

15.8

0.020

0.007

,0.001

2.3

2.5

5.5

0.866

0.0145

0.005

Abbreviations: SD, standard deviation; ER, emergency room.
a
Determined using categories defined in the Chronic Illness and Disability Payment System.13
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Admitted in 6 months post-index date

Inpatient hospitalization by AP treatment outcome
15%
*P < 0.05; **P < 0.01; ***P < 0.001

12%

n = 480
Switched

9%

n = 1,382

n = 438

Continued

Abandoned

6%

3%

0%
All

Psych

Other

Type of hospital admission
Switch vs Continue

*

*

Switch vs Abandon
Continue vs Abandon
Figure 1a Inpatient hospitalization according to antipsychotic treatment outcome.

p sychiatric hospital visits, where no significant differences
were observed, the general pattern for the remaining outpatient
service categories was switching patients having the highest
rate of service use, followed by those who continued and
those who abandoned having the lowest rates of service use.

by whether it was ER-related or not (Figure 1b). Patients
who switched and those who abandoned antipsychotics
used the ER significantly more frequently than those who
continued, regardless of whether the ER visit was categorized
as psychiatric or medical. With the exception of outpatient

Outpatient service utilization by AP treatment outcome
Use in 6 months post-index date

90%
*P < 0.05; **P < 0.01; ***P < 0.001

80%
70%
60%

n = 480

n = 1,382

n = 438

Switched

Continued

Abandoned

50%
40%
30%
20%
10%
0%
Psych

Med

ER use
Sw vs Con

***

Psych

Med

Outpatient hospital
*

Con vs Abn

**

***

Med

Outpatient physician

**
**

Sw vs Abn

Psych

Psych

Other

Other outpatient

*

***

***

***

***

***

***

***

***

***

***

Figure 1b Outpatient service use according to antipsychotic treatment outcome.
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All of these comparisons were statistically significant with
the exception of continued versus abandoned in the medical
outpatient hospitalization and switched versus continued in
the psychiatric outpatient physician categories.

Treatment outcome comparisons by
medication start type
New antipsychotic users

categories were also significantly higher in patients who
switched compared to the patients who abandoned, as were
medical inpatient hospitalization and medical outpatient hospital services. Compared to those who abandoned, patients
who continued their antipsychotics utilized significantly
higher rates of medical outpatient hospital services and both
psychiatric and other outpatient services.

Established antipsychotic users

Restarting antipsychotic users

Discussion

As shown in Figure 2b, restarting patients who switched
m edications experienced significantly higher rates of
psychiatric ER use and both psychiatric and other outpatient
service use compared to those who continued. These 3 service

In this retrospective administrative claims database analysis,
patients who switched from their index medication to a
different antipsychotic medication within 6 months were
significantly more likely to use a number of health care

Use in 6 months post-index date

As shown in Figure 2a, patients who switched antipsychotic
medications were in general more likely to utilize health
care resources than their counterparts who continued on
their index medications. Both ER-use categories, medical
outpatient hospital visits, other outpatient physician, and
other outpatient visits were all significant. The only switched
versus abandoned comparison which reached significance
was for other outpatient psychiatric visits which were higher
among those who switched. Patients who abandoned were
significantly more likely to use the ER (for both psychiatric
and medical types of visits) and were also significantly more
likely to experience a medical inpatient hospitalization than
were those who continued.

90%

As shown in Figure 2c, established patients who switched
medications experienced higher rates of psychiatric ER use
and psychiatric other outpatient services compared to those
who continued. Compared to those who abandoned, patients
who switched also experienced higher rates of medical
outpatient services, other outpatient physician services and
both other and psychiatric other outpatient services. Patients
who continued their antipsychotics utilized more medical
outpatient physician and medical other outpatient services
compared to those who abandoned. Abandoned patients utilized comparable rates of ER services to those who switched;
however, there was a small sample size in this cohort.

Service utilization by AP treatment outcome
new antipsychotic users

80%
*P < 0.05; **P < 0.01; ***P < 0.001

70%

n = 76

60%

Switched

50%

n = 314

n = 232

Continued

Abandoned

40%
30%
20%
10%
0%

Psych

Med

Psych

Inpatient hospital

Sw vs Con

Med

ER use

**

Med

Outpatient hospital

*

Sw vs Abn
Con vs Abn

Psych

*

Psych

Other

Outpatient physician

*

Psych

Other

Other outpatient

**
**

*

**

**

Figure 2a Health care service utilization according to antipsychotic treatment outcome: new users. In 622 patients with available data.
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90%

Service utilization by AP treatment outcome
restarting antipsychotic users

80%
*P < 0.05; **P < 0.01; ***P < 0.001

70%
60%
50%

n = 87
Switched

n = 376

n = 169

Continued

Abandoned

40%
30%
20%
10%
0%

Psych

Med

Psych

Inpatient hospital

Sw vs Con

Med

ER use

Psych

Med

Outpatient hospital

Psych

Other

Outpatient physician

Psych

Other outpatient

**

Sw vs Abn

*

*

Con vs Abn

Other

*

***

**

***

***

*

*

*

Figure 2b Health care service utilization according to antipsychotic treatment outcome: restarters. In 632 patients with available data.

Use in 6 month post-index date

resources, including making ER visits and being hospitalized,
compared with their counterparts who continued on their
index antipsychotic medications. It is unclear whether
the greater resource use observed among individuals who
switched medications is a downstream consequence of the
switch, a function of baseline differences in severity, or some

combination of the two. The greater number of comorbid
conditions and higher rates of prior psychiatric ER use
among switchers compared to those who continue, suggests
that baseline severity is an important contributor to the
higher use of services in the outcome period. Rapid changes
in antipsychotic treatment may result from a poor match

Service utilization by AP treatment outcome
established antipsychotic users

90%
80%
70%

*P < 0.05; **P < 0.01; ***P < 0.001

60%

n = 317

n = 692

50%

Switched

Continued

n = 37
Abandoned

40%
30%
20%
10%
0%

Psych

Med

Psych

Inpatient hospital

Sw vs Con
Sw vs Abn
Con vs Abn

Med

ER use

Psych

Med

Outpatient hospital

Psych

Other

Outpatient physician

**

Psych

Other

Other outpatient

*
*

*

**

*

***
***

Figure 2c Health care utilization according to antipsychotic treatment outcome: established users. In 1,046 patients with available data.
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between patient and medication (ie, inadequate response or
intolerability of side effects), erratic clinical decision making,
erratic patient behavior, poorly integrated accessible systems
of care, difficulties with access to care, and/or the cost of care
(including medication copayments).
Patients who switched antipsychotic medications were
more likely to use a number of health care services, including
hospitalization in particular. Some general medical service
utilization could be related to management of medication side
effects. It is not clear why switching antipsychotic medications
was associated with more frequent h ospitalization for
nonpsychiatric conditions. However, these findings are
broadly consistent with higher rates of acute relapses into
active psychosis requiring intensive or emergent care in
patients who discontinue treatment. Such patients may
experience substantial medical complications or physical
injury resulting from acute psychotic relapses with attendant
deficits in judgment, including suboptimal self-care of medical
conditions; dangerous behavioral responses to delusions;
agitation; violence; being victimized; and/or making suicide
attempts.10,11 The distinction between psychiatric and medical
service use is somewhat artificial and subject to the accuracy
with which the reason(s) for the visit is coded.
Similar to patients who switched, those who abandoned
their index antipsychotic also utilized more ER services than
those who continued. For the majority of other services,
however, abandoned patients utilized fewer resources than
both those who continued and those who switched. One
possible explanation for this finding is that patients who
abandon their medication may be poorly engaged in proactive
psychiatric care.
Although smaller sample sizes in some of the cohorts
limited the ability to draw definitive conclusions, it is worthwhile to examine differences in resource utilization patterns
among the new, restarting, and established patient cohorts.
ER Use: The new and established cohorts had very similar
patterns of ER use. For both psychiatric and medical ER
visits, those who switched and those who abandoned their
index antipsychotic each used the ER more frequently than
those who continued. Among restarting users, however, those
who switched antipsychotics used the ER more frequently
than both other groups.

Non-ER outpatient services
Among established users, those who switched used outpatient
services at least as frequently as those who continued and
generally more frequently than those who abandoned. Among
restarting antipsychotic users, however, switchers tended to

Patient Preference and Adherence 2010: 4
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use services most frequently, followed by those who continue
and finally those who abandon. Among new antipsychotic
users, those who switched used outpatient services with the
greatest frequency in many categories. Unlike the restarting
and established cohorts, however, service use for the abandoned group was often equivalent to that of the cohort who
continued. Event rates ,10% for inpatient hospitalization
made it difficult to discern a clear pattern.
Compared with their counterparts who continued on their
index medications, patients who switched had significantly
more comorbid conditions at baseline and were significantly
more likely to have previously visited the ER. Consequently, it
is unclear whether the higher rate of ER use among switchers
during the follow-up period represented a continuation of the
previous trend, a consequence of the medication switch, or
some combination of these factors. Regardless of the reason,
the increased use of these medical services warrants close
inspection, and future research should seek to characterize
the proportion of ER service use specifically attributable to
switching.
Future studies are also needed to further evaluate the
actual costs and cost-effectiveness of switching antipsychotic
treatments. Perhaps not surprisingly, one recent post-hoc
analysis of an open-label study concluded that switching
from one atypical antipsychotic to another because of
inadequate efficacy or tolerability resulted in quality-of-life
benefits (increased health utilities) and was projected to
be cost effective.14 In contrast to other pharmacoeconomic
analyses of schizophrenia treatments,15–18 the present study
estimated health care costs indirectly via rates of health care
resource utilization and did not capture health and other care
not covered by Medicaid. These include medications during
inpatient treatment, as well as privately paid treatment,
charity care, family care, and shelter care. As noted in the
Methods, this study did not distinguish between individuals
using a particular service once and those with multiple
visits or prolonged inpatient stays. Such an examination is
necessary to assess the full economic impact of switching
antipsychotics. The present study also compared health care
utilization among patients switching (vs those continuing
or abandoning) any antipsychotic medication; however,
there may be differences in treatment adherence between
individual antipsychotic agents.19
Other potential limitations of this study include its:
1) retrospective and exploratory nature; 2) limited follow-up
period (6 months); and 3) definition of continued treatment
adherence on the basis of prescriptions filled, which are not
necessarily accurate barometers of actual medication use.
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As in other exploratory analyses, data were not adjusted for
multiple comparisons. Further, an observational study cannot
exclude potential biases resulting from unmeasured and other
confounders. One potential confound is an imbalance of
established antipsychotic medication users (45.5% of eligible
patients); these users had significantly more comorbid conditions than new users or restarters, and patients switching medications also had significantly more comorbidities than those
who continued on, or abandoned, their index medications. It is
possible that some of these comorbidities are related to medication side effects that may have motivated either the index or
the subsequent antipsychotic medication change.
In many administrative claims database analyses such as
this one, baseline patient-level data and on-treatment clinical
information are limited. For example, in the present analysis,
data on race/ethnicity were not available for approximately
25% of participants. On the basis of a limited baseline period
of 1 year before the index date and an average patient age
of 37 years, it is unlikely that all patients in the “new-user”
category were actually completely treatment naïve.
Given limited patient-level data, the data also could not
be rigorously analyzed according to the reason for treatment
discontinuation (eg, suboptimal efficacy, tolerability), which
can influence health care resource utilization. By predefined
eligibility criteria, the age at the index date ranged from
18 to 50 years to exclude children, adolescents, and patients
with dementia. Thus, our findings may not be generalizable
to these patient segments. Our analysis was also based on
Medicaid data from a single state (California) and hence
may not be representative of the overall Medicaid population with schizophrenia. Our findings are also not necessarily
generalizable to the overall US schizophrenia population
and may not apply to dual-eligible Medicaid recipients with
schizophrenia. In light of these considerations, our results
need to be further evaluated in larger, longer-term prospective studies conducted in naturalistic clinical settings and
involving more heterogeneous patient populations.
Because our evaluation period was limited to days 91 to
180 after the index date, it is not possible to conclude that all
patients defined as having abandoned therapy did not actually
obtain other forms of care at a later date. On the other hand,
our 90-day reference period to define medication abandonment was longer than has been reported in other analyses.
Two previous administrative claims studies reported increased
rates of hospitalization with gaps as short as 10 days.20,21
We selected a 90-day refill gap to reduce the number of
individuals misclassified as having abandoned antipsychotic
treatment. However, one possible consequence of this
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d ecision is that some individuals classified as having switched
antipsychotics in our study, would have been considered as
having a clinically significant gap (ie, abandoning therapy)
in other studies. Previous studies have also demonstrated
higher hospitalization rates associated with longer medication
gaps.20 Therefore, it is possible that differences in service
use between those switching antipsychotic medications
or continuing their index medications in the present study
might have been smaller if our analysis had employed a
shorter reference period to define abandonment. To the extent
that both medication switching and abandonment represent
suboptimal medication treatment outcomes, however, this
distinction may be less critical.

Conclusion
Patients who switch antipsychotic treatments experience
significantly increased health resource utilization compared
with their counterparts remaining on their initial medications.
Future studies are needed to confirm these findings and identify
potential baseline or on-treatment predictors of favorable
treatment responses, in order to minimize adverse human and
economic outcomes of switching.
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